Beijing Bohui Innovation Biotechnology Group Co., Ltd. ("Bohui Group"), founded in 2001, has evolved into a high-tech biomedical enterprise that integrates R&D, production, sales, and after-sales service into a comprehensive system. Headquartered in Zhongguancun Life Science Park in Beijing, the company operates a 40,000-square-meter integrated R&D center. In May 2012, Bohui Group was listed on the Shenzhen Stock Exchange ChiNext (Stock Code: 300318).

In the field of inspection and testing, Bohui Group possesses strong independent R&D capabilities. Leveraging microfluidic technology, the Group has developed a fully automated nucleic acid detection system, acclaimed as a "laboratory on a chip". Additionally, through the wholly-owned acquisition of Advion, a US-based company, Bohui Group has concentrated its efforts on the application of mass spectrometry analysis within the life sciences sector, offering customers outstanding mass spectrometry products and exceptional user experience.

Within the strategic emerging biopharmaceutical sector, Bohui Group operates 3 blood products manufacturing plants in Shijiazhuang  City (Hebei Province), Langfang  City (Hebei Province), and Shantou City (Guangdong Province). Furthermore, It is currently new-generation blood products facilities in Qujing City(Yunnan Province) and Hohhot City (Inner Mongolia Autonomous Region); Additionally, Langfang facility facility also produces selected vaccine products.